Literature DB >> 11481348

Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design.

K R Hess, J L Abbruzzese.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11481348     DOI： 10.1200/JCO.2001.19.15.3445

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Current approaches to novel therapeutics in pancreatic cancer.

Authors:  Corina E Akerele; Irina Rybalova; Howard L Kaufman; Sridhar Mani
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

Review 2.  Drug development in pancreatic cancer: finally, biology begets therapy.

Authors:  Steven J Cohen; Neal J Meropol
Journal:  Int J Gastrointest Cancer       Date:  2002

Review 3.  Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression.

Authors:  Klaus Felix; Matthias M Gaida
Journal:  Int J Biol Sci       Date:  2016-01-28       Impact factor: 6.580

Review 4.  Novel therapies for pancreatic adenocarcinoma.

Authors:  Simona M Pino; Henry Q Xiong; David McConkey; James L Abbruzzese
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.945

Review 5.  Novel therapies for pancreatic adenocarcinoma.

Authors:  Simona M Pino; Henry Q Xiong; David McConkey; James L Abbruzzese
Journal:  Curr Gastroenterol Rep       Date:  2004-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.